# A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

> **NCT07738510** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Halia Therapeutics, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Anemia

## Interventions

- **DRUG:** Ofirnoflast

## Key facts

- **NCT ID:** NCT07738510
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738510, "A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*